Evolus Inc.
Organization details
- Legal name
- Evolus Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Newport Beach
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EOLS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001570562
- EIN
- 46-1385614
Board of directors
-
Albert G. White III · DirectorSince 2024
-
Brady Stewart · DirectorSince 2023
-
David Moatazedi · Director · See RemarksSince 2023
-
David N. Gill · DirectorSince 2023
-
Karah Herdman Parschauer · DirectorSince 2023
-
Peter C. Farrell · DirectorSince 2023
-
Robert Hayman · DirectorSince 2023
-
Simone Blank · DirectorSince 2023
-
Vikram Malik · DirectorSince 2023
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
0.0%
Board connections
5 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
Arcturus Therapeutics Holdings Inc. Same sectorvia Peter C. Farrell
-
Biomerica Inc. Same sectorvia David Moatazedi
-
ResMed Inc. Same sectorvia Peter C. Farrell
-
Telix Pharmaceuticals Limited Same sectorvia David N. Gill
-
Tenaya Therapeutics Inc. Same sectorvia Karah Herdman Parschauer
-
The Cooper Companies Inc. Same sectorvia Albert G. White III
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,838,881
- 7 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | David Moatazedi Director, Officer (See Remarks) | Open-market sale | −105,108 | $9.04 | $950,176 |
| Mar 20, 2026 | Avelar Rui Officer (See Remarks) | Open-market sale | −3,119 | $4.75 | $14,815 |
| Mar 20, 2026 | David Moatazedi Director, Officer (See Remarks) | Open-market sale | −13,669 | $4.75 | $64,928 |
| Mar 17, 2026 | David Moatazedi Director, Officer (See Remarks) | Open-market sale | −116,720 | $4.89 | $570,761 |
| Mar 17, 2026 | Avelar Rui Officer (See Remarks) | Open-market sale | −29,996 | $4.89 | $146,680 |
| Mar 16, 2026 | David Moatazedi Director, Officer (See Remarks) | Option exercise | +67,489 | — | — |
| Mar 16, 2026 | Avelar Rui Officer (See Remarks) | Option exercise | +8,804 | — | — |
| Feb 17, 2026 | Karah Herdman Parschauer Director | Grant or award | +45,559 | — | — |
| Feb 17, 2026 | Brady Stewart Director | Grant or award | +45,559 | — | — |
| Feb 17, 2026 | Mitchell Tatjana Officer (Chief Financial Officer) | Grant or award | +121,489 | — | — |
| Feb 17, 2026 | Albert G. White III Director | Grant or award | +45,559 | — | — |
| Feb 17, 2026 | David Moatazedi Director, Officer (See Remarks) | Grant or award | +313,212 | — | — |
| Feb 17, 2026 | Vikram Malik Director | Grant or award | +45,559 | — | — |
| Feb 17, 2026 | Avelar Rui Officer (See Remarks) | Grant or award | +94,913 | — | — |
| Feb 17, 2026 | David N. Gill Director | Grant or award | +45,559 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Evolus Inc.
How many directors are on Evolus Inc.'s board?
Evolus Inc.'s board has 9 directors: Albert G. White III, Brady Stewart, David Moatazedi, David N. Gill, Karah Herdman Parschauer, Peter C. Farrell, Robert Hayman, Simone Blank and Vikram Malik.
Are Evolus Inc. insiders buying or selling shares?
Over the last 12 months, Evolus Inc. insiders made no open-market purchases and sold $1.8 million of shares in 7 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="evolus-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.